Ibio Inc (IBIO)
iBio, Inc. is a preclinical-stage biotechnology company listed on the NASDAQ under the ticker IBIO. The company focuses on developing AI-enabled antibody solutions for cardiometabolic disease, obesity, and oncology. Its technology portfolio includes EngageTx, a CD3 T-cell engager antibody platform; ShieldTx, a masking technology designed to create conditionally activated antibodies; StableHu, an AI-based antibody optimization platform; and an epitope-steering approach intended to direct antibodies to specific regions of target proteins.
iBio’s pipeline includes programs such as IBIO-101, an anti-CD25 monoclonal antibody, as well as antibody candidates targeting CCR8, MUC16, EGFRvIII, and a TROP-2 x CD3 bispecific program. The company also has a collaboration with AstralBio to identify and develop antibodies for obesity and related cardiometabolic conditions. Founded in 2008 and headquartered in San Diego, California, iBio changed its name from iBioPharma, Inc. in 2009.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-IBIO
|
$1.33
|
0.2% Upside
|
Fair
|
$5.69
|
327.7% Upside
|
Bargain
|
Fair
|
0.0%
|
November 17, 2026
|
1.0x
|
855.3x
|
85.529 M
|
-312.35 K
|
2.7%
|
81.0%
|
1.1
|
72.0%
|
